Ovation

Ovation.io is a precision medicine startup specializing in the generation and integration of high-value human genomic and multi-omics data, linked with detailed longitudinal clinical information. The company’s platform is designed to accelerate drug discovery and development by providing disease-specific genomic and transcriptomic data cohorts that offer the scale, diversity, and depth necessary for impactful biomarker discovery, target identification, and patient stratification.

For life sciences organizations, Ovation.io delivers comprehensive datasets that support research across various therapeutic areas. Notably, the company has launched specialized datasets, such as a comprehensive research data set of whole genome sequences and longitudinal clinical records for patients treated with GLP-1 agonists, and a multi-omics database for oncology in partnership with ONCare Alliance. Their inflammatory bowel disease (IBD) dataset provides immediate access to diverse patient cohorts, with deep sequencing and curated clinical data spanning the entire patient journey.

For clinical laboratories, Ovation.io offers Ovation LIMS, a laboratory information management system tailored to the needs of molecular diagnostic labs, and the Ovation Research Network, which enables labs to contribute remnant samples for research, thereby supporting the discovery of new treatments.

Ovation.io’s approach emphasizes data quality, diversity, and accessibility, aiming to de-risk and expedite the development of new therapies through robust, clinically relevant datasets.

Keywords: precision medicine, genomics, multi-omics, clinical data, drug discovery, biomarker discovery, target identification, patient stratification, laboratory information management, molecular diagnostics, GLP-1, oncology, inflammatory bowel disease, data integration, research network, biobank